Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: A case-control study

Andrea Nicolini, D. Campani, P. Miccoli, C. Spinelli, A. Carpi, M. Menicagli, P. Ferrari, G. Gadducci, G. Rossi, M. Fini, G. Giavaresi, V. Bonazzi, R. Giardino

Research output: Contribution to journalArticle

Abstract

VEGF is a specific mitogen and survival factor for endothelial cells and a key promoter of angiogenesis in physiological and pathological conditions. Nevertheless, VEGF tissue evaluation in cancer patients as a prognostic factor compared to the conventional histological and biological parameters is still controversial. In this case-control study, tissue VEGF was retrospectively determined by immunohistochemistry and related to T, N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 in 129 breast cancer patients. Seventy-four of these patients had developed distant metastases postoperatively. The remaining 55 patients had remained disease-free >10 years after surgery. In 17 (13%) of the 129 patients (six with distant metastases and eleven disease-free) tissue and plasma VEGF were concomitantly evaluated. In univariate analysis no significant differences in VEGF and tumor size were found between metastatic and disease-free patients, whereas there were significant differences in N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 (p ranging from 0.001 to 0.0001). In multivariate analysis VEGF showed less significance than N, ER, c-erbB-2, MIB-1 and cyclin D1 (p=0.01 2, p=0.007, p=0.005, p=0.005, p=0.002 and p=0.001, respectively). VEGF was a significant unfavorable prognostic indicator only in the N+ subset (p=0.015), while ER (p=0.05 and p=0.021) and MIB-1 (p=0.031 and p=0.022) were significant in both the N+ and N- sub-groups. In multivariate analysis in the 74 metastatic cases VEGF did not show any significance in relation to disease-free interval and overall survival from the time of mastectomy and from the time of relapse, whereas N and PgR did (p ranging from 0.018 to 0.001). In conclusion, tissue VEGF does not seem, a suitable candidate to replace conventional histological and other common biological prognostic factors in breast cancer.

Original languageEnglish
Pages (from-to)275-281
Number of pages7
JournalInternational Journal of Biological Markers
Volume19
Issue number4
Publication statusPublished - Oct 2004

Fingerprint

Vascular Endothelial Growth Factor A
Case-Control Studies
Tissue
Breast Neoplasms
Cyclin D1
Multivariate Analysis
Physiologic Neovascularization
Pathologic Neovascularization
Neoplasm Metastasis
Survival
Mastectomy
Endothelial cells
Biological Factors
Mitogens
Surgery
Tumors
Neoplasms
Endothelial Cells
Immunohistochemistry
Plasmas

Keywords

  • Breast cancer
  • Prognostic indicators
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Immunology
  • Biochemistry

Cite this

Nicolini, A., Campani, D., Miccoli, P., Spinelli, C., Carpi, A., Menicagli, M., ... Giardino, R. (2004). Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: A case-control study. International Journal of Biological Markers, 19(4), 275-281.

Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer : A case-control study. / Nicolini, Andrea; Campani, D.; Miccoli, P.; Spinelli, C.; Carpi, A.; Menicagli, M.; Ferrari, P.; Gadducci, G.; Rossi, G.; Fini, M.; Giavaresi, G.; Bonazzi, V.; Giardino, R.

In: International Journal of Biological Markers, Vol. 19, No. 4, 10.2004, p. 275-281.

Research output: Contribution to journalArticle

Nicolini, A, Campani, D, Miccoli, P, Spinelli, C, Carpi, A, Menicagli, M, Ferrari, P, Gadducci, G, Rossi, G, Fini, M, Giavaresi, G, Bonazzi, V & Giardino, R 2004, 'Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: A case-control study', International Journal of Biological Markers, vol. 19, no. 4, pp. 275-281.
Nicolini, Andrea ; Campani, D. ; Miccoli, P. ; Spinelli, C. ; Carpi, A. ; Menicagli, M. ; Ferrari, P. ; Gadducci, G. ; Rossi, G. ; Fini, M. ; Giavaresi, G. ; Bonazzi, V. ; Giardino, R. / Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer : A case-control study. In: International Journal of Biological Markers. 2004 ; Vol. 19, No. 4. pp. 275-281.
@article{359f0b1aa8f64468affa0fad22b5478c,
title = "Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer: A case-control study",
abstract = "VEGF is a specific mitogen and survival factor for endothelial cells and a key promoter of angiogenesis in physiological and pathological conditions. Nevertheless, VEGF tissue evaluation in cancer patients as a prognostic factor compared to the conventional histological and biological parameters is still controversial. In this case-control study, tissue VEGF was retrospectively determined by immunohistochemistry and related to T, N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 in 129 breast cancer patients. Seventy-four of these patients had developed distant metastases postoperatively. The remaining 55 patients had remained disease-free >10 years after surgery. In 17 (13{\%}) of the 129 patients (six with distant metastases and eleven disease-free) tissue and plasma VEGF were concomitantly evaluated. In univariate analysis no significant differences in VEGF and tumor size were found between metastatic and disease-free patients, whereas there were significant differences in N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 (p ranging from 0.001 to 0.0001). In multivariate analysis VEGF showed less significance than N, ER, c-erbB-2, MIB-1 and cyclin D1 (p=0.01 2, p=0.007, p=0.005, p=0.005, p=0.002 and p=0.001, respectively). VEGF was a significant unfavorable prognostic indicator only in the N+ subset (p=0.015), while ER (p=0.05 and p=0.021) and MIB-1 (p=0.031 and p=0.022) were significant in both the N+ and N- sub-groups. In multivariate analysis in the 74 metastatic cases VEGF did not show any significance in relation to disease-free interval and overall survival from the time of mastectomy and from the time of relapse, whereas N and PgR did (p ranging from 0.018 to 0.001). In conclusion, tissue VEGF does not seem, a suitable candidate to replace conventional histological and other common biological prognostic factors in breast cancer.",
keywords = "Breast cancer, Prognostic indicators, Vascular endothelial growth factor (VEGF)",
author = "Andrea Nicolini and D. Campani and P. Miccoli and C. Spinelli and A. Carpi and M. Menicagli and P. Ferrari and G. Gadducci and G. Rossi and M. Fini and G. Giavaresi and V. Bonazzi and R. Giardino",
year = "2004",
month = "10",
language = "English",
volume = "19",
pages = "275--281",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - Vascular endothelial growth factor (VEGF) and other common tissue prognostic indicators in breast cancer

T2 - A case-control study

AU - Nicolini, Andrea

AU - Campani, D.

AU - Miccoli, P.

AU - Spinelli, C.

AU - Carpi, A.

AU - Menicagli, M.

AU - Ferrari, P.

AU - Gadducci, G.

AU - Rossi, G.

AU - Fini, M.

AU - Giavaresi, G.

AU - Bonazzi, V.

AU - Giardino, R.

PY - 2004/10

Y1 - 2004/10

N2 - VEGF is a specific mitogen and survival factor for endothelial cells and a key promoter of angiogenesis in physiological and pathological conditions. Nevertheless, VEGF tissue evaluation in cancer patients as a prognostic factor compared to the conventional histological and biological parameters is still controversial. In this case-control study, tissue VEGF was retrospectively determined by immunohistochemistry and related to T, N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 in 129 breast cancer patients. Seventy-four of these patients had developed distant metastases postoperatively. The remaining 55 patients had remained disease-free >10 years after surgery. In 17 (13%) of the 129 patients (six with distant metastases and eleven disease-free) tissue and plasma VEGF were concomitantly evaluated. In univariate analysis no significant differences in VEGF and tumor size were found between metastatic and disease-free patients, whereas there were significant differences in N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 (p ranging from 0.001 to 0.0001). In multivariate analysis VEGF showed less significance than N, ER, c-erbB-2, MIB-1 and cyclin D1 (p=0.01 2, p=0.007, p=0.005, p=0.005, p=0.002 and p=0.001, respectively). VEGF was a significant unfavorable prognostic indicator only in the N+ subset (p=0.015), while ER (p=0.05 and p=0.021) and MIB-1 (p=0.031 and p=0.022) were significant in both the N+ and N- sub-groups. In multivariate analysis in the 74 metastatic cases VEGF did not show any significance in relation to disease-free interval and overall survival from the time of mastectomy and from the time of relapse, whereas N and PgR did (p ranging from 0.018 to 0.001). In conclusion, tissue VEGF does not seem, a suitable candidate to replace conventional histological and other common biological prognostic factors in breast cancer.

AB - VEGF is a specific mitogen and survival factor for endothelial cells and a key promoter of angiogenesis in physiological and pathological conditions. Nevertheless, VEGF tissue evaluation in cancer patients as a prognostic factor compared to the conventional histological and biological parameters is still controversial. In this case-control study, tissue VEGF was retrospectively determined by immunohistochemistry and related to T, N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 in 129 breast cancer patients. Seventy-four of these patients had developed distant metastases postoperatively. The remaining 55 patients had remained disease-free >10 years after surgery. In 17 (13%) of the 129 patients (six with distant metastases and eleven disease-free) tissue and plasma VEGF were concomitantly evaluated. In univariate analysis no significant differences in VEGF and tumor size were found between metastatic and disease-free patients, whereas there were significant differences in N, ER, PgR, c-erbB-2, p53, MIB-1 and cyclin D1 (p ranging from 0.001 to 0.0001). In multivariate analysis VEGF showed less significance than N, ER, c-erbB-2, MIB-1 and cyclin D1 (p=0.01 2, p=0.007, p=0.005, p=0.005, p=0.002 and p=0.001, respectively). VEGF was a significant unfavorable prognostic indicator only in the N+ subset (p=0.015), while ER (p=0.05 and p=0.021) and MIB-1 (p=0.031 and p=0.022) were significant in both the N+ and N- sub-groups. In multivariate analysis in the 74 metastatic cases VEGF did not show any significance in relation to disease-free interval and overall survival from the time of mastectomy and from the time of relapse, whereas N and PgR did (p ranging from 0.018 to 0.001). In conclusion, tissue VEGF does not seem, a suitable candidate to replace conventional histological and other common biological prognostic factors in breast cancer.

KW - Breast cancer

KW - Prognostic indicators

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=19944428356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=19944428356&partnerID=8YFLogxK

M3 - Article

C2 - 15646833

AN - SCOPUS:19944428356

VL - 19

SP - 275

EP - 281

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -